Literature DB >> 33968579

Exploring the endogenous potential of Hemidesmus indicus against breast cancer using in silico studies and quantification of 2-hydroxy-4-methoxy benzaldehyde through RP-HPLC.

Akash Anand Bansod1, Gnanam Ramasamy1, Bharathi Nathan1, Rajamani Kandhasamy1, Meenakshisundaram Palaniappan1, Santhanakrishnan Vichangal Pridiuldi1.   

Abstract

Being a woman and getting older are the main risk factors for breast cancer. While admitting the increasing prevalence of breast cancer among females globally, there is an increasing urge for widening the range of chemical compounds that can act as potential inhibitors for certain cancer target receptors. Current investigation involves virtually screening of 19 protein receptors having major role in signal transduction pathway of breast cancer development against 47 compounds present in Hemidesmus indicus. Virtual screening and supplementary analysis were performed using freely available softwares, tools and online servers. To obtain meaningful results, a comparative scenario was created by screening FDA-approved drugs/drug analogues against the same 19 receptors by keeping all the parameters same as to that of ligands. Two ligands namely Taraxasteryl acetate and Rutin were found to be the best ligands with high binding affinity towards six protein receptors establishing strong receptor ligand interactions. Furthermore, the major volatile compound, a high demand flavouring agent and an isomer of vanillin, namely 2-hydroxy-4-methoxy benzaldehyde (MBALD) specifically found in the roots of Hemidesmus, was quantified by RP-HPLC using a reverse phase C-18 column. The methanolic extract of fresh roots was found to contain 0.221 mg of MBALD/gram of tissue. From the current investigation, it could be surmised that Hemidesmus indicus had demonstrated its potential in both pharmaceuticals and the food industry. © King Abdulaziz City for Science and Technology 2021.

Entities:  

Keywords:  Breast cancer; HPLC; MBALD; Virtual screening

Year:  2021        PMID: 33968579      PMCID: PMC8068754          DOI: 10.1007/s13205-021-02768-x

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  51 in total

Review 1.  The role of estrogen in the initiation of breast cancer.

Authors:  J Russo; Irma H Russo
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

Review 2.  AKT as a Therapeutic Target for Cancer.

Authors:  Mengqiu Song; Ann M Bode; Zigang Dong; Mee-Hyun Lee
Journal:  Cancer Res       Date:  2019-02-26       Impact factor: 12.701

3.  Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.

Authors:  Julie A Tucker; Tobias Klein; Jason Breed; Alexander L Breeze; Ross Overman; Chris Phillips; Richard A Norman
Journal:  Structure       Date:  2014-11-20       Impact factor: 5.006

4.  Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.

Authors:  Tiffany Tsui; W Todd Miller
Journal:  Biochemistry       Date:  2015-05-13       Impact factor: 3.162

5.  The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction.

Authors:  Saghir Akhtar; Ibrahim Fadil Benter
Journal:  Bioimpacts       Date:  2013-01-26

6.  Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor.

Authors:  Kenji Ogura; Takanori Shiga; Masashi Yokochi; Satoru Yuzawa; Terrence R Burke; Fuyuhiko Inagaki
Journal:  J Biomol NMR       Date:  2008-10-02       Impact factor: 2.835

7.  Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.

Authors:  R L Rocha; S G Hilsenbeck; J G Jackson; C L VanDenBerg; C n Weng; A V Lee; D Yee
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

8.  PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.

Authors:  Sun Hee Park; Koichi Ito; William Olcott; Igor Katsyv; Gwyneth Halstead-Nussloch; Hanna Y Irie
Journal:  Breast Cancer Res       Date:  2015-06-19       Impact factor: 6.466

9.  Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a.

Authors:  Nahida Srabovic; Zlata Mujagic; Jasminka Mujanovic-Mustedanagic; Adaleta Softic; Zdeno Muminovic; Adi Rifatbegovic; Lejla Begic
Journal:  Int J Breast Cancer       Date:  2013-12-12

10.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.

Authors:  Roman C Hillig; Brice Sautier; Jens Schroeder; Dieter Moosmayer; André Hilpmann; Christian M Stegmann; Nicolas D Werbeck; Hans Briem; Ulf Boemer; Joerg Weiske; Volker Badock; Julia Mastouri; Kirstin Petersen; Gerhard Siemeister; Jan D Kahmann; Dennis Wegener; Niels Böhnke; Knut Eis; Keith Graham; Lars Wortmann; Franz von Nussbaum; Benjamin Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.